CUE
Cue Biopharma, Inc.
There isn't enough reported data to score CUE yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
CUE Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
CUE's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
CUE PE Valuation
CUE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
CUE Forward outlook
There aren't enough analyst estimates for CUE to show an outlook.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
CUE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$25.82 | -$9.92 |
| Q1 2026 | -$4.38 | +$14.82 |
| Q4 2025 | -$8.40 | +$13.20 |
| Q3 2025 | -$12.90 | +$14.40 |
| Q2 2025 | -$15.90 | +$13.50 |
| Q1 2025 | -$19.20 | +$12.90 |
| Q4 2024 | -$21.60 | +$11.70 |
| Q3 2024 | -$27.30 | +$8.40 |
CUE is still losing money, but far less than before: $25.82 per share over the past year, against $57.00 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over CUE on earnings quality, reporting a profit while its opponent remains loss making.
CUE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $7.9M | +167% |
| Q1 2026 | $5.7M | +1251% |
| Q4 2025 | $21.9M | +1292% |
| Q3 2025 | $2.1M | -36% |
| Q2 2025 | $3M | +11% |
| Q1 2025 | $421K | -75% |
| Q4 2024 | $1.6M | -13% |
| Q3 2024 | $3.3M | +59% |
CUE's revenue is growing: $8M last quarter, up 167% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1113% | -821 points |
| Q1 2026 | -94% | +2827 points |
| Q4 2025 | 9% | +620 points |
| Q3 2025 | -353% | -89 points |
| Q2 2025 | -292% | +98 points |
| Q1 2025 | -2921% | -2184 points |
| Q4 2024 | -611% | +148 points |
| Q3 2024 | -264% | +280 points |
CUE's operating margin was −1113% last quarter, down 821 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH's revenue has held roughly level: $113B last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over CUE on profitability, with a higher operating margin.
CUE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$29M | -$25.6M |
| Q1 2026 | -$11.1M | -$2.7M |
| Q4 2025 | -$1.1M | +$8M |
| Q3 2025 | -$9M | -$1.5M |
| Q2 2025 | -$3.4M | +$6.6M |
| Q1 2025 | -$8.3M | +$1.5M |
| Q4 2024 | -$9M | +$1.9M |
| Q3 2024 | -$7.5M | +$273K |
CUE has burned cash in almost every quarter: −$50M over the past year, against −$28M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over CUE on cash generation, producing positive trailing cash flow while its opponent burns cash.
CUE Net Leverage
CUE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
CUE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.8 | Neutral |
| Stochastic | 12.2 | Oversold |
CUE's weekly RSI is 44 (neutral) and its Stochastic is 12 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
CUE PE vs Healthcare Sector
CUE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
CUE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $22.1 | 21% below |
| 20 week MA | $26.9 | 35% below |
| 50 week MA | $20.1 | 13% below |
| 100 week MA | $23.3 | 25% below |
| 200 week MA | $46.7 | 63% below |
CUE is in a downtrend: it's below all five of its weekly moving averages, and 63% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over CUE on trend strength, trading above more of its moving averages.
CUE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $524.1 | $393.6 | -25% |
| 2021 | $393.6 | $373.2 | -5.2% |
| 2022 | $373.2 | $82.5 | -78% |
| 2023 | $82.5 | $79.2 | -4% |
| 2024 | $79.2 | $31.2 | -61% |
| 2025 | $31.2 | $9.74 | -69% |
| 2026 YTD | $9.74 | $17.5 | +80% |
CUE has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.